Xilio therapeutics announces $11.3 million private placement equity financing

Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for xtx301, a tumor-activated, il-12, and xtx101, a tumor-activated, fc-enhanced anti-ctla-4, and leveraging the company's promising research platform for tumor-activated bispecific and cell engager molecules
XLO Ratings Summary
XLO Quant Ranking